Neurogenesis, Inc. (NEUN)
ValueMarkers Composite Index
98% below intrinsic value ($0)
Neurogenesis, Inc. (NEUN) — VMCI valuation read
Neurogenesis, Inc. (NEUN) carries a VMCI composite of 55/100, 5 points above the Healthcare sector median of 50. Among mid-cap names, that gap places NEUN in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).
The NEUN insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.
**Investor frame.** Value reads NEUN trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -2.2x leaves covenant headroom, the line to track on Neurogenesis, Inc.'s next 10-Q.
NEUN rose 2.3% over the trailing 7 days, with a -8.2% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.